Met Life Investment Management, LLC Replimune Group, Inc. Transaction History
Met Life Investment Management, LLC
- $18 Billion
- Q4 2024
A detailed history of Met Life Investment Management, LLC transactions in Replimune Group, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 37,659 shares of REPL stock, worth $477,516. This represents 0.0% of its overall portfolio holdings.
Number of Shares
37,659
Previous 35,134
7.19%
Holding current value
$477,516
Previous $385,000
18.44%
% of portfolio
0.0%
Previous 0.0%
Shares
31 transactions
Others Institutions Holding REPL
# of Institutions
161Shares Held
74.9MCall Options Held
38.4KPut Options Held
43.7K-
Baker Bros. Advisors LP New York, NY11MShares$140 Million1.48% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11MShares$139 Million0.02% of portfolio
-
Redmile Group, LLC San Francisco, CA4.91MShares$62.2 Million4.65% of portfolio
-
Black Rock Inc. New York, NY4.71MShares$59.8 Million0.0% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.97MShares$50.3 Million8.12% of portfolio
About Replimune Group, Inc.
- Ticker REPL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,306,700
- Market Cap $625M
- Description
- Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...